| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
The compound's primary biological target is enterovirus 71 (EV71). It also effectively suppresses the activity of the METTL3/METTL14 complex, which is a key regulator of N6-methyladenosine (m6A) RNA methylation. By inhibiting this complex, the compound can potentially alter the stability, splicing, and translation of both host and viral RNAs. The dual targeting of a viral pathogen and a host epigenetic regulator represents a unique mechanism of action. The compound's high potency against EV71 (EC50 = 94 nM) suggests that its primary antiviral effect may be through a direct interaction with a viral component or a host factor critical for the viral life cycle.
|
|---|---|
| ln Vitro |
In HeLa cells, antiviral agent 23 (0-100 μM) suppresses the replication of CVA21 and EV68, with EC50 values of 36.4 and 8.9 μM, respectively[1]. METTL3/METTL14's enzymatic activity is inhibited by antiviral drug 23 (100 μM) by 74.45%[1]. Antiviral agent 23 (0-100 μM) exhibits antiviral activity against EV71 and, with an EC50 value of 94 nM, inhibits the strain BrCr's reproduction in RD cells[1].
In vitro, the compound demonstrates potent antiviral activity against enterovirus 71, with an EC50 value of 94 nM. Its cytotoxicity has been evaluated in several cell lines. In human HeLa cells, the compound showed a CC50 value greater than 100 μM. In mouse B16 and human G361 cells, the IC50 values were greater than 166.7 μM. However, it exhibited more significant antiproliferative activity against human CCRF-CEM cells, with an IC50 value of 19.1 μM. These data suggest that the compound is relatively well-tolerated in many cell types but may have antiproliferative effects in specific cell lines. |
| ln Vivo |
Information regarding the in vivo activity of this compound in animal models is not currently available. Its biological activity has been characterized primarily through in vitro assays. The lack of in vivo data means that its pharmacokinetic properties, bioavailability, and efficacy in a living organism are unknown. Further studies are required to determine whether the promising in vitro antiviral activity translates into therapeutic benefit in an animal model. The compound's dual mechanism of action, targeting both viral replication and host methylation, warrants investigation in appropriate in vivo models of enterovirus infection.
|
| Enzyme Assay |
The non-cellular enzyme or receptor binding assay for this compound has not been explicitly described in available literature. Given that it inhibits the METTL3/METTL14 complex, a potential biochemical assay could involve measuring the methyltransferase activity of the purified complex in the presence of the compound. This would be performed using a radioactive or fluorescent methyl donor (e.g., S-adenosylmethionine) and a synthetic RNA substrate. The inhibitory effect could be quantified by measuring the reduction in methyl group transfer. However, such a detailed biochemical characterization has not been reported, and the primary activity data is derived from cell-based assays.
|
| Cell Assay |
The in vitro cellular assay for this compound typically involves infecting susceptible cell lines, such as rhabdomyosarcoma (RD) cells or HeLa cells, with enterovirus 71. The compound is added at various concentrations, and after a suitable incubation period (e.g., 48-72 hours), the extent of viral replication is measured. This is often done by determining the viral titer using a plaque assay or by measuring the expression of viral proteins using immunofluorescence or western blotting. The compound's effect on METTL3/METTL14 activity in cells can be assessed by measuring global m6A levels in cellular RNA using a dot blot assay or by using a specific m6A antibody for immunoprecipitation followed by sequencing.
|
| Animal Protocol |
The in vivo animal experiment workflow for this compound has not been established. If an animal study were to be designed, a common approach would be to use a mouse model of enterovirus 71 infection. This could involve infecting neonatal mice with a mouse-adapted strain of EV71 via an intracranial or intraperitoneal route. The compound would then be administered at various doses and routes (e.g., oral, intraperitoneal) to evaluate its protective efficacy. The primary endpoints would include survival rate, clinical symptom score, and viral load in target tissues (e.g., brain, muscle). Histopathological analysis of tissues would also be conducted to assess tissue damage and inflammation.
|
| References |
| Molecular Formula |
C18H21N5O4
|
|---|---|
| Molecular Weight |
371.390443563461
|
| Exact Mass |
371.159
|
| CAS # |
35940-03-5
|
| PubChem CID |
10339188
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
1.5
|
| tPSA |
126
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
27
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CC(=CC=C1)CNC2=C3C(=NC=N2)N(C=N3)[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O
|
| InChi Key |
WBJVJFOITZTVRG-SCFUHWHPSA-N
|
| InChi Code |
InChI=1S/C18H21N5O4/c1-10-3-2-4-11(5-10)6-19-16-13-17(21-8-20-16)23(9-22-13)18-15(26)14(25)12(7-24)27-18/h2-5,8-9,12,14-15,18,24-26H,6-7H2,1H3,(H,19,20,21)/t12-,14-,15-,18-/m1/s1
|
| Chemical Name |
(2R,3S,4R,5R)-2-(hydroxymethyl)-5-[6-[(3-methylphenyl)methylamino]purin-9-yl]oxolane-3,4-diol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6926 mL | 13.4629 mL | 26.9259 mL | |
| 5 mM | 0.5385 mL | 2.6926 mL | 5.3852 mL | |
| 10 mM | 0.2693 mL | 1.3463 mL | 2.6926 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.